INCB-057643

N/A

Report date: 2025/05/20 20:00:09
NME

Base Information

Drug NameINCB-057643
Drug Alias NameINCB-57643INCB-057643LIMBER-103
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain and extra terminal domain protein inhibitors
TargetsBromodomain and extra terminal domain protein
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisMyeloproliferative Disorders +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesIncyte Biosciences (Shanghai) Co LtdThe University Of Texas MD Anderson Cancer CenterPatheon Inc
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersMyelodysplastic Syndromes
Inactive IndicationsSolid tumoursSarcoma, Ewing

Other Information

ATC CodeN/A
Related LinksN/A